About PILA PHARMA
PILA PHARMA is a privately held clinical stage pharmaceutical company based in Malmö, Sweden.
The company is developing a TRPV1 antagonist, XEN-D0501, as a novel type of oral anti-diabetic agent.
XEN-D0501 is a synthetic small molecule that was in-licensed in 2016.
Prior to in-licensing, XEN-D0501 had been found to have a good safety profile in other (non-diabetic) patient groups.
PILA PHARMA has to date completed two phase 2a clinical trials (PP-CT01 and PP-CT02), that both demonstrated that XEN-D0501 is well tolerated by people with type 2 diabetes.
Further, PP-CT02, demonstrated that XEN-D0501 (administered as 4 mg BID for 28 days) – with statistical significance versus placebo – enhance the endogenous insulin response to oral glucose.

Announcement
Development of a novel drug to treat diabetes.
Investor presentation by CEO Dorte X. Gram at the BioStock Life Science Summit 2020, Lund, Sweden.
Watch the presentation in English here
(17-Nov-2020)
The Malmö-based company Pila Pharma, which has a drug candidate for type 2 diabetes, will be listed on one of the Swedish stock exchanges in the second quarter of next year.
Read the article in Swedish here
(17-Nov-2020)

Pila Pharma has scheduled its arrival on the Swedish stock market for May next year with the goal of fetching SEK 50m for developing the firm’s diabetes tablet leading up to phase III.
An interview with CEO Dorte X. Gram by Medwatch, Denmark.
Read the article in English here
Read the article in Danish here
(17-Nov-2020)
Our Opinion and Concept Paper on the role of TRPV1 in diabetes published in Trends in Molecular Medicine.
Read the paper here
Novo-forsker gjorde ph.d.-projekt til biotekselskab og forbereder nu fase 2-studie.
An interview with CEO Dorte X. Gram by Medwatch, Denmark.
Read the article in Danish here
Om jag har rätt kan detta bli gigantisk.
An interview with CEO Dorte X. Gram by BioStock, Sweden.
Read the article in Swedish here
PILA PHARMA är klar med uppstartsfasen och flyttar ut från inkubatorn.
An interview with CEO Dorte X. Gram published by Medeon, Sweden.
Read the article in Swedish here
Nytt piller skal göra livet lättare för diabetiker – svensk bolag vill förändra sjukvården.
An interview with CEO Dorte X. Gram published in Veckans Affärer, Sweden.
Winning prize to PILA PHARMA at the Almi Invest pitch competition 2016, sponsored by Veckans Affärer.
Check out the resulting article here
Uppstickaren som vill ta plats i läkemedelsindustrin.
An interview with CEO Dorte X. Gram published in ‘DI Almedalen, Distributed with Dagens Industri, Sweden.
Read the article in Swedish here
“Min uppfinning kom och hämtade tillbaka mig”
Dr. Dorte X. Gram, CEO of PILA PHARMA was interviewed by Sydsvenskan, Sweden.
Read the article in Swedish here
I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.